Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP Chief Legal Officer | February 13, 2026 | February 18, 2026 |
| INVACARE HOLDINGS CorpIVC · Entity 86444 | Director | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,450 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,450 · Balance 8,450 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
INVACARE HOLDINGS Corp
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 104,499 |
Reported balance
After 2022-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-04-01 · Grant · Acquired 39,474 · Balance 104,499 F1: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2023. F2: Includes 13,388 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan, all of which vest in full on May 15, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted pursuant to the Invacare Corporation 2018 Equity Compensation Plan in an exempt transaction under Rule 16b-3. These restricted stock units vest in full on May 15, 2023.
F2: Includes 13,388 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan, all of which vest in full on May 15, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 01:05 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000026 · form4.xml · derivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,450 Underlying: Common Stock · 8,450 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 4,916 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · derivative · entry 10 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,834 Underlying: Common Stock · 4,916 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,940 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · derivative · entry 9 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,940 Underlying: Common Stock · 1,940 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · derivative · entry 8 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,190 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,514 | $201.18 | $304,586.52 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · nonDerivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,807 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 4,916 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · nonDerivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 931 | $201.18 | $187,298.58 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,405 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,059 | $201.18 | $213,049.62 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,396 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,190 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000015 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004454 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,575 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 807 | $142.54 | $115,029.78 |
DisclosureSEC source: 0001127602-25-004454 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,265 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004454 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,940 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · derivative · entry 8 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,880 Underlying: Common Stock · 1,940 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · derivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,190 Underlying: Common Stock · 2,190 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 591 | $141.35 | $83,537.85 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,497 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 643 | $141.35 | $90,888.05 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,148 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 14,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003954 · form4.xml · derivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Common Stock · 14,750 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 20,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026727 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Susan H. Alexander 2021 Irrevocable Trust Disclosed balance after: 20,082 F1 · kind: This transaction involved a gift of securities by the reporting person to an irrevocable trust for the benefit of the reporting person's children on November 5, 2024. The reporting person's spouse is the trustee of the trust. Read SEC document |
| November 05, 2024 Filed Nov 7, 2024 21:23 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 20,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026727 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,601 F1 · kind: This transaction involved a gift of securities by the reporting person to an irrevocable trust for the benefit of the reporting person's children on November 5, 2024. The reporting person's spouse is the trustee of the trust. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,012 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · derivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,012 shares Expires 2024-02-18 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,614 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · derivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,012 Underlying: Common Stock · 1,614 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionPerformance Stock Unit · Derivative | 3,423 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · derivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,423 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 781 | $219.08 | $171,101.48 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,683 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,656 | $219.08 | $362,796.48 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,850 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004786 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,575 Underlying: Common Stock · 2,575 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 938 | $240.98 | $226,039.24 |
DisclosureSEC source: 0001127602-24-004786 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,083 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004786 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,190 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004311 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,380 Underlying: Common Stock · 2,190 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 655 | $240.30 | $157,396.50 |
DisclosureSEC source: 0001127602-24-004311 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,446 Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004311 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:16 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,820 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004311 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 5,820 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:27 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 3,423 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002799 · form4.xml · derivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,423 Underlying: Common Stock · 3,423 shares Expires 2024-02-18 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 18, 2021. The PSUs will vest on February 18, 2024. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:49 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,702 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006502 · form4.xml · derivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,626 Underlying: Common Stock · 1,702 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:49 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,920 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006502 · form4.xml · derivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,328 Underlying: Common Stock · 1,920 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:49 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 929 | $278.38 | $258,615.02 |
DisclosureSEC source: 0001127602-23-006502 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,911 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:49 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006502 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,770 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · derivative · entry 8 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,770 shares Expires 2023-02-12 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · derivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,770 Underlying: Common Stock · 1,448 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · derivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,150 Underlying: Common Stock · 2,575 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 2,737 | $286.30 | $783,603.10 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,920 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 701 | $286.30 | $200,696.30 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,657 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 764 | $286.30 | $218,733.20 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,910 Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 02:46 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 23:42 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,570 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004573 · form4.xml · derivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,570 Underlying: Common Stock · 6,570 shares Expires 2026-02-08 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 2/8/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.